The presence of any pre‐existing cardiovascular disease in patients receiving anti–PD–1 or anti–PD‐L1 therapy was significantly associated with mortality (HR: 1.12, 95% CI: 1.09–1.14, p < 0.001) (Figure 1). Here, CD274 is linked to cardiovascular disorder.